Male Reproductive Cancers

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

By

Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.

New Therapeutic Directions in the Management of Prostate Cancer

New Therapeutic Directions in the Management of Prostate Cancer

By

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

By

Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

By

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

PET/CT Accurately Localizes Recurrent Prostate Cancer

PET/CT Accurately Localizes Recurrent Prostate Cancer

By

Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

By

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

By

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

By

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

By

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

By

The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

By

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

By

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

By

A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

By

The BMH online survey allows patients to enter comorbidity data at home prior to consultation.

Testicular Cancer Treatment Regimens

Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.

Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

By

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

By

The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

By

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

By

Patients in both treatment arms had a PFS of about 9 months.

Single PSA screening increases prostate cancer detection but does not change mortality

In this randomized controlled trial, men aged 50 to 69 received an invitation to take a single PSA test or were unscreened.

Confronting Racial Disparities in Prostate Cancer Survival Outcomes

Confronting Racial Disparities in Prostate Cancer Survival Outcomes

By

African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.

Higher Radiation Dose May Not Improve Prostate Cancer Outcomes

Higher Radiation Dose May Not Improve Prostate Cancer Outcomes

By

Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.

5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer

5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer

By

A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.

Single PSA Screening Does Not Improve Prostate Cancer-Related Mortality

Single PSA Screening Does Not Improve Prostate Cancer-Related Mortality

By

Recommendations about population-wide PSA screening are mixed, with some studies suggesting that the potential benefits of early diagnosis are outweighed by overtreatment.

Are Liquid Biopsies Trustworthy?

Are Liquid Biopsies Trustworthy?

By

A study could not determine whether one liquid biopsy panel is more accurate than another overall.

Apalutamide: First FDA-Approved Agent for Non-Metastatic Castration-Resistant Prostate Cancer

Apalutamide: First FDA-Approved Agent for Non-Metastatic Castration-Resistant Prostate Cancer

By

Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.

Emerging Therapies for Prostate Cancer

Emerging Therapies for Prostate Cancer

By

New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

By

In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

By

COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

By

It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs